Westchester Capital Management (New York)’s Pear Therapeutics, Inc. Warrant PEARW Stock Holding History

Westchester Capital Management (New York)’s Portfolio PEARW Stock Details PEARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-63,181	Closed	-$69	–	393
2023 Q2	$69	Hold	63,181	–	–	﹤0.01%	321
2023 Q1	$1.2K	Hold	63,181	–	–	﹤0.01%	354
2022 Q4	$9.41K	Hold	63,181	–	–	﹤0.01%	404
2022 Q3	$11K	Hold	63,181	–	–	﹤0.01%	446
2022 Q2	$7K	Hold	63,181	–	–	﹤0.01%	418
2022 Q1	$51K	Hold	63,181	–	–	﹤0.01%	391
2021 Q4	$38K	Hold	63,181	–	–	﹤0.01%	376
2021 Q3	$60K	Buy	+63,181	New	+$65.8K	﹤0.01%	336

Westchester Capital Management (New York)'s PEARW Position: Q3 2023 in Review

Westchester Capital Management (New York) sold out of Pear Therapeutics, Inc. Warrant (PEARW) in Q3 2023, closing a stake of 63,181 shares — an estimated $69 sold.

Westchester Capital Management (New York) first reported a position in PEARW in Q3 2021 and held it in 8 quarters. The position peaked at $60K in Q3 2021. 0 funds tracked by Wall St. Rank hold PEARW as of Q3 2023.

Westchester Capital Management (New York) reported no remaining Pear Therapeutics, Inc. Warrant position as of Q3 2023 after selling out during the quarter.
Westchester Capital Management (New York) sold 63,181 Pear Therapeutics, Inc. Warrant shares in Q3 2023, an estimated $69.
Westchester Capital Management (New York) first reported a position in Pear Therapeutics, Inc. Warrant in Q3 2021 and held it in 8 quarters.
Westchester Capital Management (New York)'s Pear Therapeutics, Inc. Warrant position peaked at $60K in Q3 2021.
0 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Warrant as of Q3 2023.

Based on Westchester Capital Management (New York)'s 13F filing for Q3 2023, filed 8 Nov 2023.